Seabrook, South Carolina, United States.
Department of Endocrinology and Diabetology, Universidad Central del Ecuador, Quito, Ecuador.
Growth Horm IGF Res. 2020 Jun;52:101318. doi: 10.1016/j.ghir.2020.101318. Epub 2020 Mar 31.
Both rhGH and rhIGF-I are signaling molecules with the capacity to restore the rate of growth in certain subsets of slowly growing children. In some instances, heights attained at or near the time of cessation of linear growth are indistinguishable from the height distribution of the community as a whole or from the height distribution expected based on the heights of biological parents. The GH: IGF-I signaling system is sequential, forming a continuous loop wherein GH will stimulate production of IGF-I and IGF-I will inhibit production of GH. This feature suggests that a deficiency of GH will be accompanied by a deficiency of IGF-I and that treatment of GH deficiency with rhGH will restore IGF-I and the subnormal growth of combined GH: IGF-I deficiency. Although logical, this proposition is not always true. rhGH and rhIGF-I are distinct polypeptides, with distinct cell surface receptors and distinct intracellular signaling pathways both capable of amplifying distinct, yet overlapping, patterns of gene replication, protein synthesis and metabolic activities. These features suggest that neither treatment with rhGH nor rhIGF-I alone will invariably recapitulate the combined activities of the GH: IGF-I system, At the present time, this proposition appears both logical and true. The possibility that combined rhGH and rhIGF-I treatment can accomplish that which neither monotherapy can has been examined in gene knock-out experiments in animals and direct comparisons of GH, IGF-I and combined GH: IGF- treatments in animals and in children with short stature, normal GH and low IGF-I (primary IGF-I deficiency). In these experimental models, the growth rates with combined rhGH and rhIGF-I treatment exceed those of either monotherapy. The extent to which this proposition can be generalized to various short stature populations remains to be determined.
rhGH 和 rhIGF-I 都是具有恢复某些生长缓慢儿童生长速度能力的信号分子。在某些情况下,线性生长停止时或接近停止时达到的身高与整个社区的身高分布或基于生物学父母身高的预期身高分布没有区别。GH:IGF-I 信号系统是连续的,形成一个连续的循环,其中 GH 将刺激 IGF-I 的产生,而 IGF-I 将抑制 GH 的产生。这一特征表明,GH 缺乏将伴随着 IGF-I 缺乏,rhGH 治疗 GH 缺乏将恢复 IGF-I 和联合 GH:IGF-I 缺乏的生长不良。虽然合乎逻辑,但这一主张并不总是正确的。rhGH 和 rhIGF-I 是不同的多肽,具有不同的细胞表面受体和不同的细胞内信号通路,都能够放大不同但重叠的基因复制、蛋白质合成和代谢活性模式。这些特征表明,rhGH 或 rhIGF-I 单独治疗都不会始终再现 GH:IGF-I 系统的联合活性。目前,这一主张似乎既合乎逻辑又正确。联合 rhGH 和 rhIGF-I 治疗能否完成单药治疗无法完成的任务,这一问题已在动物基因敲除实验和 GH、IGF-I 以及联合 GH:IGF-治疗在生长激素正常、IGF-I 低(原发性 IGF-I 缺乏)的矮小儿童中的直接比较中得到了检验。在这些实验模型中,联合 rhGH 和 rhIGF-I 治疗的生长速度超过了单药治疗。这一主张在多大程度上可以推广到各种矮小症人群仍有待确定。